The document discusses acid peptic disorders and treatments such as proton pump inhibitors (PPIs). It notes that while all PPIs are generally effective, they differ in properties like onset of action and ability to control symptoms rapidly. Rabeprazole is highlighted as a PPI that may have advantages over others due to its faster onset of activity from more rapid activation rates, potentially providing quicker symptom relief. Clinical studies demonstrate rabeprazole's effectiveness in treating gastroesophageal reflux disease.

1. Acid Peptic Disorders The Lesser Known Truths

5. Complications of GERD GERD complications Oesophageal erosion Oesophageal ulcer Oesophageal stricture Replacement of normal esophageal epithelium with abnormal (Barrett's) epithelium Pulmonary aspiration

7. Currently Practised Therapy

8. Which PPI Can Promise Rapid Symptom Relief With Disease Resolution? Omeprazole Lansoprazole Pantoprazole Esomeprazole

10. PPI Variations OCH 3 3,5–(CH 3 ) 2 CH 3 Ome 3-CH 3 3-CH 3 R I CH 2 CH 2 CH 2 OCH 3 CH 2 CF 3 R H Rabe H Lanso R II PPI R I R R II

12. The Need of Today An Ideal PPI What Is That?

15. Rabeprazole – Milestones Launched in USA August 1999 Launched in India February 2002 Launched in 14 European countries September 1998 Launched in UK May 1998 Launched in Japan 1997

19. Rabeprazole – Comparative Pharmacokinetics 1 97% 1-2 Esome-prazole 1.3 98% 2.4 Panto-prazole 0.85-2 0.5-1 1.6 Half-life (hours) 94.8-97.5% 95% 97% Protein binding (%) 2-5 0.5-3.5 1.7 Time to peak plasma concentration (hours) Rabe-prazole Ome-prazole Lanso-prazole Pharmaco-kinetic Parameter

20. Rabeprazole – Comparative Pharmacodynamics Percent inhibition of the H+/K+-ATPase 100% 47% 66% At 10 minutes Activation time (minutes) 100% 83% 100% At 45 minutes 7.2 84 90 At a pH of 5.1 1.3 2.8 2.0 At a pH of 1.2 Rabeprazole Omeprazole Lansoprazole Pharmaco-dynamic Parameter Pharmacodynamic Parameters of the PPIs

21. Rabeprazole – Increased Acid suppression * Barnett JL et al, Managed Care 2001

22. Rabeprazole – Faster symptom relief * Barnett JL et al, Managed Care 2001

29. Rabeprazole Clinical Studies

30. Patients' Perceptions of GERD: Evidence From the Trenches* Most persons with heartburn, experience night attacks - Nocturnal acid breakthrough [NAB]

31. Nocturnal Heartburn Grades in GERD: Evidence From the Trenches*

34. Rabeprazole In GERD

36. Rabeprazole in GERD -0.81 -1.10 -0.65 -0.94 119  2 -1.05 -0.87 Ome-prazole 20mg. -0.84 -0.69 Ome-prazole 20mg.  5 -1.46 -1.27 48 Rabe-prazole 20mg. Rabe-prazole 20mg. -1.21 -1.02 92  3 Day 7 Day 3 Changes in heartburn score from baseline Number of patients Heartburn episodes during screening [per week] Comparison of Rabeprazole & Omeprazole in erosive GERD: heartburn relief after 3 & 7 days

37. Rabeprazole for Healing of GERD Dig Dis Sci 2001 Mar;46(3):587-96 Treatment duration ranged from < or =8 weeks

38. Rabeprazole in Long Term GERD Maintenance Dig Dis Sci 2000;45:845-853 Treatment duration = 52 weeks

39. Rabeprazole In GU & DU

40. Rabeprazole in GU Aliment. Phramacol ther. 1998, 12:789-795 Treatment rates verified in 227 patients at 3 & 6 weeks

41. Rabeprazole / Omeprazole in Gastric Ulcer 86% 84% 6 80% 89% 6 67% 75% 6 83% 90% 6 44% 52% 6 65% 82% 6 59% 60% 3 Complete resolution Night time pain severity 75% 88% 3 Improvement Daytime pain severity 79% 82% 3 Improvement Frequency 61% 68% 3 Complete resolution 29% 34% 3 Complete resolution 61% 71% 3 Improvement Omeprazole 20mg Rabeprazole 20mg Week Pain Parameter Comparison of Rabeprazole & Omeprazole in GU symptom relief after 3 & 6 weeks

42. Rabeprazole in DU Clin Ther 2000 Mar;22(3):266-80; discussion 265 Treatment duration ranged from  4 weeks for DU

43. Rabeprazole In Helicobacter Pylori Infection

46. Rabeprazole For Special Conditions